A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors

• Sponsor: Celgene (Industry)
• Overall Status: Active, not recruiting
• CT.gov ID: NCT03257631
• Collaborator: (none)
• Enrollment: 53
• Locations: 23
• Arm: 1
• Anticipated Duration (Months): 66.8
• Patients Per Site: 2.3
• Patients Per Site Per Month: 0

Study Details

Study Description

Brief Summary

This study will assess the efficacy, safety and tolerability of pomalidomide in children and young adults aged 1 to < 21 years with recurrent or progressive primary brain tumors in one of four primary brain tumor types: high-grade glioma (HGG), medulloblastoma, ependymoma and diffuse intrinsic pontine glioma (DIPG).

Condition or Disease	Intervention/Treatment	Phase
Central Nervous System Neoplasms; Medulloblastoma	Drug: Pomalidomide; Drug: Pomalidomide	Phase 2

Detailed Description

The study will consist of 4 parallel groups of participants, one for each of the following primary brain tumor types: high-grade glioma, medulloblastoma, ependymoma and DIPG. A Simon's Optimal two-stage study design will be applied to each group and enrollment will occur as follows:

• Stage 1: Nine participants will be enrolled in each brain tumor type group

• Stage 2: If during Stage 1, ≥ 2 participants achieves either an objective response (either complete response or partial response) within the first 6 cycles of treatment (or within the first 3 cycles for DIPG participants), or a long-term stable disease, an additional 11 participants shall be enrolled; otherwise no additional participants will be enrolled into that group.

• If a total of 5 or more participants across all 20 participants in a given group (Stage 1 and 2) evaluable for the primary endpoint are observed as having either an objective response (either complete response or partial response) within the first 6 cycles of treatment (or within the first 3 cycles for DIPG participants) or a long-term stable disease, pomalidomide will be considered effective in that disease indication.

Once treatment has been discontinued, participants will be followed up for up to 5 years from enrollment of the last participant.

Participants who withdraw from either stage for reasons other than disease progression prior to completing Cycle 1 of study treatment will be replaced.

Study Design

• Study Type: Interventional
• Actual Enrollment: 53 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A PHASE 2 CLINICAL STUDY OF POMALIDOMIDE (CC-4047) MONOTHERAPY FOR CHILDREN AND YOUNG ADULTS WITH RECURRENT OR PROGRESSIVE PRIMARY BRAIN TUMORS
• Actual Study Start Date: Aug 22, 2017
• Actual Primary Completion Date: Nov 23, 2018
• Anticipated Study Completion Date: Mar 18, 2023

Arms and Interventions

Arm

Intervention/Treatment

Experimental: Pomalidomide Pomalidomide will administered at a starting dose of 2.6 m2/day. Pomalidomide will be provided as either a capsule (0.5 mg, 1 mg, 2 mg, 3 mg or 4 mg) or as an oral suspension (2 mg/mL).

Drug: Pomalidomide; : Subjects will be administered pomalidomide on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle and will continue treatment for up to 24 cycles or until disease progression, withdrawal of consent/assent or unresolved toxicities as described in the protocol.; Other Names: CC-4047 ; Drug: Pomalidomide; Pomalidomide will be provided as gelatin capsules and as an oral suspension. The starting dose will be 2.6 mg/m²/day, administered on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle.; Other Names: CC-4047 Pomalyst®

Outcome Measures

Primary Outcome Measures

1. Percentage of Participants With an Objective Response or Long-term Stable Disease [6 months (first 6 cycles) or 3 months (first 3 cycles) for participants in the DIPG group]

   Objective response and long-term stable disease rate was defined as the percentage of participants who achieved either an objective response, defined as a complete response (CR) or partial response (PR) in the first 6 cycles of treatment (or within 3 cycles for DIPG), or long-term stable disease (SD) defined as SD maintained for ≥ 6 cycles (≥ 3 cycles for DIPG), measured from first dose date. Disease assessments were based on magnetic resonance imaging (MRI) assessed by an independent central review. CR: Disappearance of all lesions and no new lesions. PR: A reduction of ≥ 50% in the size of measurable lesions compared to baseline, and/or persistence of non-target lesions with no progression or decrease in size. SD: A decrease of < 50% or an increase of < 25% in the size of measurable lesions and no evidence of new lesions, response does not meet the criteria for CR, PR, or progressive disease, and/or the persistence of non-target lesions with no progression or decrease in size.

Secondary Outcome Measures

1. Percentage of Participants Who Achieved an Objective Response [6 months (first 6 cycles) or 3 months (first 3 cycles) for participants in the DIPG group]

   Objective response rate was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) within the first 6 cycles of treatment (or within 3 cycles for participants in the DIPG group). Disease assessments were based on MRI and assessed by an independent central review. CR: Disappearance of all lesions and no new lesions. PR: A reduction of ≥ 50% in the size of measurable lesions compared to baseline, and/or the persistence of non-target lesions with no progression or decrease in size.

2. Percentage of Participants With Long-term Stable Disease [6 months (first 6 cycles) or 3 months (first 3 cycles) for participants in the DIPG group]

   Long-term stable disease (SD) rate was defined as the percentage of participants who achieved SD maintained for ≥ 6 cycles (or > 3 cycles for DIPG), measured from the date of first dose of treatment. Disease assessments were based on MRI and assessed by an independent central review. SD: A decrease of < 50% or an increase of < 25% in the size of measurable lesions and no evidence of new lesions, response does not meet the criteria for CR, PR, or progressive disease, and/or the persistence of non-target lesions with no progression or decrease in size.

3. Kaplan-Meier Estimate of Duration of Response [From the first dose of pomalidomide to the data cut-off date of 15 March 2019; median overall time on follow-up was 4.86 months (3.78, 5.65, 4.04, and 8.38 months in each group respectively).]

   Duration of response is defined as the time from the date of the first objective response (complete response or partial response) to disease progression, for participants with a response. Participants who did not have disease progression or had not died were censored at the time of their last disease assessment or at the time of start of new anticancer therapy, whichever occurred first. Progressive disease (PD): ≥ 25% increase in the size of the measurable lesions taking as a reference the smallest disease measurement recorded since the start of protocol therapy (nadir), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions, or if spine MRI and/or lumbar cerebrospinal fluid (CSF) cytology were previously negative and became positive.

4. Kaplan-Meier Estimate of Progression-Free Survival (PFS) [From the first dose of pomalidomide to the data cut-off date of 15 March 2019; median overall time on follow-up was 4.86 months (3.78, 5.65, 4.04, and 8.38 months in each group respectively).]

   Progression-free survival was defined as the time from the date of first dose of pomalidomide until the date progressive disease (PD) was first observed or until the date of death due to any cause, whichever occurred first. Participants who did not have PD or had not died at the time of analysis were censored at the time of their last disease assessment or at the start of new anticancer therapy, whichever occurred first. Progressive Disease (PD): ≥ 25% increase in the size of the measurable lesions taking as a reference the smallest disease measurement recorded since the start of protocol therapy (nadir), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions, or if spine MRI and/or lumbar CSF cytology were previously negative and became positive.

5. Kalan-Meier Estimate of Overall Survival [From the first dose of pomalidomide to the data cut-off date of 15 March 2019; median overall time on follow-up was 4.86 months (3.78, 5.65, 4.04, and 8.38 months in each group respectively).]

   Overall survival was defined as the time from the date of the first dose to the date of death (any cause). Participants who were alive were censored at the last known time that the participant was alive.

6. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) [From first dose of pomalidomide until 28 days after the last dose; median treatment duration was 84 days in the DIPG group, 112.0 days in the ependymoma group, 40.5 days in the high-grade glioma group and 57.0 days in the medulloblastoma group.]

   Treatment-emergent adverse events were defined as any adverse events (AE) occurring from the first dose of pomalidomide until 28 days after the last dose. The severity of each AE was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 and according to the following scale: Grade 1: Mild (transient or mild discomfort; no limitation in activity or medical intervention required); Grade 2: Moderate (mild to moderate limitation in activity, assistance may be needed; minimal medical intervention required); Grade 3: Severe (marked limitation in activity, assistance and medical intervention required, hospitalization possible); Grade 4: Life-threatening (extreme limitation in activity, significant assistance or medical intervention required, hospitalization or hospice care probable); Grade 5: Death. Drug-related AEs are those suspected by the Investigator as being related to administration of study drug.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 1 Year to 21 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Subject is 1 to < 21 years of age at the time of signing the Informed Consent Form/Informed Assent Form (ICF/IAF).

2. Subject (when applicable, parental/legal representative) must understand and voluntarily sign an ICF/IAF prior to any study-related assessments/procedures being conducted.

3. Subject has received at least one prior standard therapy (or generally accepted upfront therapy if no standard exists) and have no known curative therapy.

4. Subject has a diagnosis of high-grade glioma, medulloblastoma, ependymoma or diffuse intrinsic pontine glioma (DIPG) that is recurrent or progressive. Subjects with neurofibromatosis type 1 (NF-1) associated tumors are eligible if they meet all other eligibility criteria.

5. Subject has histological verification of tumor either at the time of diagnosis or recurrence. Subjects with DIPG are exempt from histologic verification if they have typical magnetic resonance imaging (MRI) findings of DIPG

6. Subject has measurable disease defined as a tumor that is measurable in 2 perpendicular diameters on MRI. For a lesion to be considered measurable, it must be at least twice the slice thickness on MRI (ie, visible on 2 or more axial slices)

7. To document the degree of tumor at study baseline, the following scan(s) must be obtained:

• A brain MRI with and without contrast (ie, gadolinium) and a spine MRI with contrast within 21 days prior to first dose of study treatment. For subjects on steroids, baseline MRI scans must be performed while on stable or decreasing dose of steroids for at least 5 days.

1. Subject has Karnofsky (age ≥ 16 years) or Lansky (age < 16 years) performance status score ≥ 50 at screening

2. Subject has adequate bone marrow function defined as:

• Peripheral absolute neutrophil count (ANC) ≥ 1000/mm³

• Platelet count ≥ 100,000/mm³ (transfusion independent defined as no platelet transfusion within 7 days and recovery from nadir)

• Hemoglobin ≥ 8 g/dL (red blood cell [RBC] transfusion is allowed)

1. Subject has adequate renal function defined as:

• Serum creatinine based on age/gender calculated using the Schwartz formula, or a 24-hour creatinine clearance or radioisotope glomerular filtration rate (GFR) (radioisotope or iothalamate) ≥ 70 mL/min/1.73 m².

1. Subject has adequate liver function defined as:

• Total bilirubin ≤ 1.5 X upper limit of normal (ULN) for current age (≤ 3 X ULN if increase in bilirubin is attributable to Gilbert's Syndrome)

• Alanine aminotransferase (ALT) (SPGT) is ≤ 3 X ULN for age

• Serum albumin ≥ 3 g/dL

1. Subject has adequate pulmonary function defined as:

• No evidence of dyspnea at rest

• A pulse oximetry ≥ 93%

1. Subject has recovered from clinically significant acute treatment related toxicities from all prior therapies. Recovery is defined as a toxicity Grade ≤ 2 (common terminology criteria for adverse events [CTCAE] v. 4.03).

2. Subject has no significant worsening in clinical status for a minimum of 7 days prior to first dose of study drug.

3. Subject (and when applicable, with parental/legal representative) is willing and able to adhere to the study visit schedule and other protocol requirements.

4. Females of Childbearing Potential (FCBP) and male subjects who have reached puberty (and when applicable, with parental/legal representative) must agree to undergo physician-approved reproductive education and discuss the side effects of the study therapy on reproduction.

5. Females of childbearing potential must agree and meet the following conditions below:

• Medically supervised (ie, performed in a clinic) pregnancy testing, including those who commit to true abstinence. Two pregnancy tests must be conducted prior to starting pomalidomide. The first pregnancy test must be performed 10 to 14 days prior to the start of pomalidomide and the second pregnancy test must be performed within 24 hours prior to starting pomalidomide. Females of childbearing potential with regular or no menstrual cycles must also agree to have pregnancy tests weekly for the first 28 days study participation, every 28 days while on study, at study treatment discontinuation, and at Day 28 following pomalidomide discontinuation. If menstrual cycles are irregular, the pregnancy testing must occur weekly for the first 28 days of study participation and then every 14 days while on study, at study treatment discontinuation visit, and at Days 14 and 28 following pomalidomide discontinuation.

• Female subjects must, as appropriate to age and at the discretion of the study Investigator, either commit to true abstinence from heterosexual contact and/or agree to the use of two reliable forms of approved and effective contraceptive methods simultaneously. The two methods of reliable contraception must include one highly effective method (ie, oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; vasectomized partner) and one additional effective barrier method (ie, male condom, diaphragm, cervical cap) 28 days prior to starting pomalidomide, throughout the entire duration of study treatment including dose interruptions and 28 days after discontinuation of pomalidomide.

• All male and female subjects must follow all requirements defined in the pomalidomide Pregnancy Prevention Program.

1. Male subjects must, as appropriate to age and the discretion of the study physician:

• Practice true abstinence or agree to use a condom during sexual contact with a pregnant female or a female of child bearing potential while participating in the study, during dose interruptions and for at least 28 days following pomalidomide discontinuation, even if he has undergone a successful vasectomy or practices complete abstinence.

Exclusion Criteria:

1. Subject has a history of non-central line related thrombosis (arterial or venous), more than one prior central-line related thrombosis or known coagulopathy.

2. Subject has first degree family member with a known hereditary coagulopathy.

3. Subject is actively on anticoagulation therapy.

4. Subject has had major (per Investigator discretion) surgery, with the exception of tumor resection, within 21 days from first dose of study drug.

5. Subject has previously received (presence of any of the following will exclude a subject from enrollment):

• Any prior treatment with pomalidomide. Subjects who have prior treatment with other immunomodulatory compounds (thalidomide, lenalidomide) are eligible if they meet all other eligibility criteria and did not have allergic reactions or other "significant toxicity" per Investigator discretion associated with lenalidomide or thalidomide use.

• Myelosuppressive chemotherapy, immunotherapy, or any investigational agent: ≤ 21 days (≤ 42 days if a nitrosourea) prior to screening.

• Biological (anti-neoplastic) therapy: ≤ 7 days prior to screening.

• Immunomodulatory therapy: ≤ 28 days prior to screening.

• Monoclonal antibody treatment and agents with known prolonged half-lives: < 3 halflives have elapsed or ≤ 28 days prior to screening, whichever is longer.

• Prior radiation:

• Cranial irradiation, total body irradiation (TBI), or ≥ 50% radiation of pelvis ≤ 3 months prior to screening.

• Focal irradiation: ≤ 3 weeks prior to screening if radiation field involved a nontarget lesion; ≤ 6 weeks prior to screening if radiation field involved a target lesion.

Note: True disease progression following prior irradiation therapy must be confirmed by Investigator prior to screening.

• Bone marrow transplant:

• Presence of graft versus host disease (GVHD).

• < 6 months since allogeneic bone marrow transplant prior to screening.

• < 3 months since autologous bone marrow/stem cell transplant prior to screening.

• < 3 months since stem cell transplant (SCT) or Rescue without TBI with no evidence of GVHD prior to screening.

• Radioisotopes: fluorothymidine (18FLT) ≤ 72 hours prior to first dose of study drug

1. Subject has received therapy with a known moderate to potent CYP1A2 inhibitor within 14 days or 5 half-lives of first dose of study treatment (whichever is longer).

2. Subject has received colony-stimulating growth factor(s) within 7 days prior to screening (or within 14 days if subject received polyethylene glycol formulations).

3. Subject is pregnant, breast-feeding or lactating.

4. Subject has an untreated or uncontrolled infection defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment.

5. Subject has active infectious hepatitis, type A, B, or C, or chronic carriers of hepatitis C.

6. Subject has any prior history of malignancies, other than high-grade glioma, medulloblastoma, ependymoma or DIPG (Note: radiation-associated gliomas are excluded from enrollment)

7. Subject who, in the opinion of the Investigator, has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.

8. Subject has any condition including the presence of laboratory abnormalities which, in the opinion of the Investigator, places the subject at unacceptable risk if he/she were to participate in the study.

9. Subject has any condition that confounds the ability to interpret data from the study.

10. Subject has symptomatic cardiac disorders (CTCAE v. 4.03 Grade 3 and 4).

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Stanford University Cancer Center	Stanford	California	United States	94305-5750
2	University of Florida	Gainesville	Florida	United States	32611
3	Ann and Robert H Lurie Childrens Hospital of Chicago	Chicago	Illinois	United States	60611
4	National Cancer Institute	Bethesda	Maryland	United States	20892
5	Dana Farber Cancer Institute	Boston	Massachusetts	United States	02115
6	Baylor College of Medicine	Houston	Texas	United States	77030
7	Centre Oscar Lambret	Lille		France	59020
8	Centre Leon Berard	Lyon		France	69008
9	Hopital d'Enfants de la Timone	Marseille Cedex 01		France	13005
10	Institut Curie	Paris		France	75005
11	Hopital des Enfants	Toulouse		France	31059
12	CHU Nancy Hematology	Vandoeuvre les Nancy		France	54511
13	Institut Gustave Roussy Faculte de Medecine Paris Sud Service de pneumologie	Villejuif Cedex		France	94805
14	Istituto G. Gaslini Ospedale Pediatrico IRCCS	Genova		Italy
15	Fondazione IRCCS Istituto Nazionale dei Tumori	Milan		Italy	20133
16	Local Institution - 200	Milan		Italy	20133
17	Ospedale Bambin Gesu	Roma		Italy	00165
18	Hospital Universitario Vall D Hebron	Barcelona		Spain	8035
19	Hospital Infantil Universitario Nino Jesus	Madrid		Spain	28009
20	Hospital Universitario La Fe	Valencia		Spain	46026
21	Leeds General Infirmary	Leeds		United Kingdom	LS7 4SA
22	Great Ormond Street Hospital	London		United Kingdom	WC1N 3JH
23	The Royal Marsden Hospital	Sutton-Surrey		United Kingdom	SM2 5PT

Sponsors and Collaborators

• Celgene

Investigators

• Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb

Study Documents (Full-Text)

• Study Protocol - Dec 20, 2017
• Statistical Analysis Plan - Dec 20, 2017

More Information

Publications

None provided.

• Responsible Party: Celgene
• ClinicalTrials.gov Identifier: NCT03257631
• Other Study ID Numbers: CC-4047-BRN-001; U1111-1199-3348; 2016-002903-25
• First Posted: Aug 22, 2017
• Last Update Posted: Jul 12, 2022
• Last Verified: Jul 1, 2022

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Celgene: Pediatric; Brain Tumor; Central Nervous System Neoplasms; Glioma; High-grade glioma; HGG; Ependymoma; Medulloblastoma; DIPG; Diffuse intrinsic pontine gliomaProgressive; RecurrentPomalidomide; PomalystImnovid; CC-4047; Children
• Additional relevant MeSH terms: Brain Neoplasms; Medulloblastoma; Nervous System Neoplasms; Central Nervous System Neoplasms; Thalidomide; Pomalidomide

Study Results

Participant Flow

Recruitment Details	Participants were enrolled at 18 sites in France, Italy, Spain, UK, and the USA. The study consisted of 4 groups, for each of the following primary brain tumor types: diffuse intrinsic pontine glioma (DIPG), ependymoma, high-grade glioma, and medulloblastoma. The study is currently ongoing; results are reported as of 15 March 2019 data cutoff date.
Pre-assignment Detail	In stage 1 approximately 9 participants were to be enrolled in parallel to each group. If two or more participants in a group achieved an objective response or long-term stable disease within the first 6 cycles of treatment (within the first 3 cycles for DIPG) an additional 11 participants were to be enrolled in that group.

Arm/Group Title	Diffuse Intrinsic Pontine Glioma	Ependymoma	High-grade Glioma	Medulloblastoma
Arm/Group Description	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.
Period Title: Overall Study
STARTED	11	9	23	10
Received Study Drug	11	9	22	10
COMPLETED	0	0	0	0
NOT COMPLETED	11	9	23	10

Baseline Characteristics

Arm/Group Title	Diffuse Intrinsic Pontine Glioma	Ependymoma	High-grade Glioma	Medulloblastoma	Total
Arm/Group Description	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Total of all reporting groups
Overall Participants	11	9	23	10	53
Age (years) [Median (Full Range) ]
Median (Full Range) [years]	7.0	12.0	14.0	10.0	12.0
Age, Customized (Count of Participants)
≥ 1 to < 6 years	1 9.1%	2 22.2%	1 4.3%	1 10%	5 9.4%
≥ 6 to < 12 years	9 81.8%	1 11.1%	5 21.7%	6 60%	21 39.6%
≥ 12 years	1 9.1%	6 66.7%	17 73.9%	3 30%	27 50.9%
Sex: Female, Male (Count of Participants)
Female	4 36.4%	4 44.4%	8 34.8%	3 30%	19 35.8%
Male	7 63.6%	5 55.6%	15 65.2%	7 70%	34 64.2%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	4 36.4%	0 0%	6 26.1%	1 10%	11 20.8%
Not Hispanic or Latino	7 63.6%	9 100%	13 56.5%	8 80%	37 69.8%
Unknown or Not Reported	0 0%	0 0%	4 17.4%	1 10%	5 9.4%
Race/Ethnicity, Customized (Count of Participants)
American Indian or Alaskan Native	0 0%	0 0%	0 0%	0 0%	0 0%
Asian	1 9.1%	0 0%	2 8.7%	0 0%	3 5.7%
Black or African American	0 0%	0 0%	2 8.7%	0 0%	2 3.8%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%	0 0%	0 0%
White	10 90.9%	9 100%	11 47.8%	8 80%	38 71.7%
Not Collected or Reported	0 0%	0 0%	5 21.7%	2 20%	7 13.2%
Other	0 0%	0 0%	3 13%	0 0%	3 5.7%

Outcome Measures

1. Primary Outcome

Title	Percentage of Participants With an Objective Response or Long-term Stable Disease
Description	Objective response and long-term stable disease rate was defined as the percentage of participants who achieved either an objective response, defined as a complete response (CR) or partial response (PR) in the first 6 cycles of treatment (or within 3 cycles for DIPG), or long-term stable disease (SD) defined as SD maintained for ≥ 6 cycles (≥ 3 cycles for DIPG), measured from first dose date. Disease assessments were based on magnetic resonance imaging (MRI) assessed by an independent central review. CR: Disappearance of all lesions and no new lesions. PR: A reduction of ≥ 50% in the size of measurable lesions compared to baseline, and/or persistence of non-target lesions with no progression or decrease in size. SD: A decrease of < 50% or an increase of < 25% in the size of measurable lesions and no evidence of new lesions, response does not meet the criteria for CR, PR, or progressive disease, and/or the persistence of non-target lesions with no progression or decrease in size.
Time Frame	6 months (first 6 cycles) or 3 months (first 3 cycles) for participants in the DIPG group

Outcome Measure Data

Analysis Population Description

The response population consisted of all participants enrolled who met eligibility criteria relevant to efficacy, and received at least one cycle of pomalidomide if therapy was not discontinued earlier due to progressive disease (PD).

Arm/Group Title	Diffuse Intrinsic Pontine Glioma	Ependymoma	High-grade Glioma	Medulloblastoma
Arm/Group Description	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.
Measure Participants	9	9	19	9
Number (95% Confidence Interval) [percentage of participants]	0 0%	11.1 123.3%	10.5 45.7%	0 0%

2. Secondary Outcome

Title	Percentage of Participants Who Achieved an Objective Response
Description	Objective response rate was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) within the first 6 cycles of treatment (or within 3 cycles for participants in the DIPG group). Disease assessments were based on MRI and assessed by an independent central review. CR: Disappearance of all lesions and no new lesions. PR: A reduction of ≥ 50% in the size of measurable lesions compared to baseline, and/or the persistence of non-target lesions with no progression or decrease in size.
Time Frame	6 months (first 6 cycles) or 3 months (first 3 cycles) for participants in the DIPG group

Outcome Measure Data

Analysis Population Description

Response population

Arm/Group Title	Diffuse Intrinsic Pontine Glioma	Ependymoma	High-grade Glioma	Medulloblastoma
Arm/Group Description	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.
Measure Participants	9	9	19	9
Number (95% Confidence Interval) [percentage of participants]	0 0%	0 0%	5.3 23%	0 0%

3. Secondary Outcome

Title	Percentage of Participants With Long-term Stable Disease
Description	Long-term stable disease (SD) rate was defined as the percentage of participants who achieved SD maintained for ≥ 6 cycles (or > 3 cycles for DIPG), measured from the date of first dose of treatment. Disease assessments were based on MRI and assessed by an independent central review. SD: A decrease of < 50% or an increase of < 25% in the size of measurable lesions and no evidence of new lesions, response does not meet the criteria for CR, PR, or progressive disease, and/or the persistence of non-target lesions with no progression or decrease in size.
Time Frame	6 months (first 6 cycles) or 3 months (first 3 cycles) for participants in the DIPG group

Outcome Measure Data

Analysis Population Description

Response population

Arm/Group Title	Diffuse Intrinsic Pontine Glioma	Ependymoma	High-grade Glioma	Medulloblastoma
Arm/Group Description	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.
Measure Participants	9	9	19	9
Number (95% Confidence Interval) [percentage of participants]	0 0%	11.1 123.3%	5.3 23%	0 0%

4. Secondary Outcome

Title	Kaplan-Meier Estimate of Duration of Response
Description	Duration of response is defined as the time from the date of the first objective response (complete response or partial response) to disease progression, for participants with a response. Participants who did not have disease progression or had not died were censored at the time of their last disease assessment or at the time of start of new anticancer therapy, whichever occurred first. Progressive disease (PD): ≥ 25% increase in the size of the measurable lesions taking as a reference the smallest disease measurement recorded since the start of protocol therapy (nadir), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions, or if spine MRI and/or lumbar cerebrospinal fluid (CSF) cytology were previously negative and became positive.
Time Frame	From the first dose of pomalidomide to the data cut-off date of 15 March 2019; median overall time on follow-up was 4.86 months (3.78, 5.65, 4.04, and 8.38 months in each group respectively).

Outcome Measure Data

Analysis Population Description

Participants in the response population with an objective response

Arm/Group Title	Diffuse Intrinsic Pontine Glioma	Ependymoma	High-grade Glioma	Medulloblastoma
Arm/Group Description	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.
Measure Participants	0	0	1	0
Median (95% Confidence Interval) [weeks]	NA

5. Secondary Outcome

Title	Kaplan-Meier Estimate of Progression-Free Survival (PFS)
Description	Progression-free survival was defined as the time from the date of first dose of pomalidomide until the date progressive disease (PD) was first observed or until the date of death due to any cause, whichever occurred first. Participants who did not have PD or had not died at the time of analysis were censored at the time of their last disease assessment or at the start of new anticancer therapy, whichever occurred first. Progressive Disease (PD): ≥ 25% increase in the size of the measurable lesions taking as a reference the smallest disease measurement recorded since the start of protocol therapy (nadir), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions, or if spine MRI and/or lumbar CSF cytology were previously negative and became positive.
Time Frame	From the first dose of pomalidomide to the data cut-off date of 15 March 2019; median overall time on follow-up was 4.86 months (3.78, 5.65, 4.04, and 8.38 months in each group respectively).

Outcome Measure Data

Analysis Population Description

Response population

Arm/Group Title	Diffuse Intrinsic Pontine Glioma	Ependymoma	High-grade Glioma	Medulloblastoma
Arm/Group Description	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.
Measure Participants	9	9	19	9
Median (95% Confidence Interval) [weeks]	11.29	8.43	7.86	8.43

6. Secondary Outcome

Title	Kalan-Meier Estimate of Overall Survival
Description	Overall survival was defined as the time from the date of the first dose to the date of death (any cause). Participants who were alive were censored at the last known time that the participant was alive.
Time Frame	From the first dose of pomalidomide to the data cut-off date of 15 March 2019; median overall time on follow-up was 4.86 months (3.78, 5.65, 4.04, and 8.38 months in each group respectively).

Outcome Measure Data

Analysis Population Description

Response population

Arm/Group Title	Diffuse Intrinsic Pontine Glioma	Ependymoma	High-grade Glioma	Medulloblastoma
Arm/Group Description	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.
Measure Participants	9	9	19	9
Median (95% Confidence Interval) [months]	3.78	12.02	5.06	11.60

7. Secondary Outcome

Title	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Description	Treatment-emergent adverse events were defined as any adverse events (AE) occurring from the first dose of pomalidomide until 28 days after the last dose. The severity of each AE was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 and according to the following scale: Grade 1: Mild (transient or mild discomfort; no limitation in activity or medical intervention required); Grade 2: Moderate (mild to moderate limitation in activity, assistance may be needed; minimal medical intervention required); Grade 3: Severe (marked limitation in activity, assistance and medical intervention required, hospitalization possible); Grade 4: Life-threatening (extreme limitation in activity, significant assistance or medical intervention required, hospitalization or hospice care probable); Grade 5: Death. Drug-related AEs are those suspected by the Investigator as being related to administration of study drug.
Time Frame	From first dose of pomalidomide until 28 days after the last dose; median treatment duration was 84 days in the DIPG group, 112.0 days in the ependymoma group, 40.5 days in the high-grade glioma group and 57.0 days in the medulloblastoma group.

Outcome Measure Data

Analysis Population Description

The safety population included all participants who received at least 1 dose of study drug.

Arm/Group Title	Diffuse Intrinsic Pontine Glioma	Ependymoma	High-grade Glioma	Medulloblastoma
Arm/Group Description	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.
Measure Participants	11	9	22	10
Any treatment-emergent adverse event (TEAE)	11 100%	8 88.9%	21 91.3%	9 90%
TEAE related to study drug	5 45.5%	7 77.8%	14 60.9%	8 80%
Serious TEAE	8 72.7%	4 44.4%	13 56.5%	4 40%
Serious TEAE related to study drug	1 9.1%	0 0%	6 26.1%	0 0%
Grade 3/4 TEAE	8 72.7%	6 66.7%	14 60.9%	6 60%
Grade 3/4 TEAE related to study drug	3 27.3%	2 22.2%	10 43.5%	4 40%
TEAE leading to death	5 45.5%	1 11.1%	3 13%	1 10%
TEAE leading to dose reduction	1 9.1%	0 0%	2 8.7%	0 0%
TEAE leading to dose interruption	4 36.4%	3 33.3%	5 21.7%	2 20%
TEAE leading to study drug discontinuation	2 18.2%	1 11.1%	2 8.7%	0 0%

Adverse Events

Time Frame	All-cause mortality is reported from enrollment to the data cut-off date of 15 March 2019; median overall time on follow-up was 4.86 months (3.78, 5.65, 4.04, and 8.38 months in each group respectively). Adverse events are reported from the first dose of study drug until 28 days after the last dose; median treatment duration was 84 days in the DIPG group, 112.0 days in the ependymoma group, 40.5 days in the high-grade glioma group and 57.0 days in the medulloblastoma group.
Adverse Event Reporting Description	All-cause mortality is reported for all enrolled participants, regardless of whether the participant received study treatment or not. Adverse events are reported for all participants who received at least 1 dose of pomalidomide.
Arm/Group Title	Diffuse Intrinsic Pontine Glioma		Ependymoma		High-grade Glioma		Medulloblastoma
Arm/Group Description	Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.		Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.		Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.		Participants received 2.6 mg/m²/day oral pomalidomide on days 1 to 21 of each 28-day treatment cycle for up to 24 cycles or until disease progression, withdrawal of consent/assent, treatment became intolerable, or death, whichever occurred first.
All Cause Mortality
	Diffuse Intrinsic Pontine Glioma		Ependymoma		High-grade Glioma		Medulloblastoma
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	8/11 (72.7%)		5/9 (55.6%)		13/23 (56.5%)		5/10 (50%)
Serious Adverse Events
	Diffuse Intrinsic Pontine Glioma		Ependymoma		High-grade Glioma		Medulloblastoma
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	8/11 (72.7%)		4/9 (44.4%)		13/22 (59.1%)		4/10 (40%)
Blood and lymphatic system disorders
Neutropenia	0/11 (0%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
Ear and labyrinth disorders
Vertigo	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Eye disorders
Vision blurred	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Gastrointestinal disorders
Abdominal pain	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Constipation	0/11 (0%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
Nausea	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
General disorders
Fatigue	0/11 (0%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
Gait disturbance	0/11 (0%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
General physical health deterioration	2/11 (18.2%)		1/9 (11.1%)		2/22 (9.1%)		1/10 (10%)
Malaise	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Pain	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		0/10 (0%)
Infections and infestations
Anorectal infection	0/11 (0%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
Encephalitis	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Herpes zoster	0/11 (0%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
Mastoiditis	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Pneumonia	0/11 (0%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
Respiratory syncytial virus bronchitis	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Sepsis	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Metabolism and nutrition disorders
Hyponatraemia	0/11 (0%)		0/9 (0%)		1/22 (4.5%)		1/10 (10%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour haemorrhage	0/11 (0%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
Nervous system disorders
Ataxia	0/11 (0%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
Depressed level of consciousness	0/11 (0%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
Dizziness	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Dyskinesia	0/11 (0%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
Generalised tonic-clonic seizure	0/11 (0%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
Headache	1/11 (9.1%)		2/9 (22.2%)		1/22 (4.5%)		0/10 (0%)
Hemiparesis	0/11 (0%)		0/9 (0%)		3/22 (13.6%)		0/10 (0%)
Hydrocephalus	0/11 (0%)		2/9 (22.2%)		2/22 (9.1%)		0/10 (0%)
Intracranial pressure increased	1/11 (9.1%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
Monoplegia	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Neurological decompensation	1/11 (9.1%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
Paraesthesia	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Presyncope	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Seizure	0/11 (0%)		0/9 (0%)		2/22 (9.1%)		1/10 (10%)
Transient ischaemic attack	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Respiratory, thoracic and mediastinal disorders
Dyspnoea	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Pneumonitis	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Respiratory failure	0/11 (0%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
Other (Not Including Serious) Adverse Events
	Diffuse Intrinsic Pontine Glioma		Ependymoma		High-grade Glioma		Medulloblastoma
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	11/11 (100%)		8/9 (88.9%)		20/22 (90.9%)		9/10 (90%)
Blood and lymphatic system disorders
Anaemia	1/11 (9.1%)		3/9 (33.3%)		7/22 (31.8%)		2/10 (20%)
Febrile neutropenia	0/11 (0%)		0/9 (0%)		2/22 (9.1%)		0/10 (0%)
Leukopenia	3/11 (27.3%)		6/9 (66.7%)		8/22 (36.4%)		3/10 (30%)
Lymphopenia	1/11 (9.1%)		6/9 (66.7%)		6/22 (27.3%)		0/10 (0%)
Neutropenia	3/11 (27.3%)		7/9 (77.8%)		9/22 (40.9%)		4/10 (40%)
Thrombocytopenia	0/11 (0%)		3/9 (33.3%)		8/22 (36.4%)		3/10 (30%)
Cardiac disorders
Bradycardia	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Sinus tachycardia	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Eye disorders
Blindness	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Conjunctival hyperaemia	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Mydriasis	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		0/10 (0%)
Gastrointestinal disorders
Abdominal pain	3/11 (27.3%)		1/9 (11.1%)		1/22 (4.5%)		1/10 (10%)
Constipation	2/11 (18.2%)		1/9 (11.1%)		5/22 (22.7%)		3/10 (30%)
Diarrhoea	0/11 (0%)		1/9 (11.1%)		5/22 (22.7%)		2/10 (20%)
Dyspepsia	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Dysphagia	1/11 (9.1%)		0/9 (0%)		2/22 (9.1%)		0/10 (0%)
Enteritis	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Nausea	2/11 (18.2%)		1/9 (11.1%)		4/22 (18.2%)		1/10 (10%)
Odynophagia	1/11 (9.1%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
Salivary hypersecretion	0/11 (0%)		0/9 (0%)		1/22 (4.5%)		1/10 (10%)
Stomatitis	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Vomiting	2/11 (18.2%)		4/9 (44.4%)		5/22 (22.7%)		4/10 (40%)
General disorders
Asthenia	0/11 (0%)		0/9 (0%)		3/22 (13.6%)		1/10 (10%)
Fatigue	2/11 (18.2%)		1/9 (11.1%)		4/22 (18.2%)		2/10 (20%)
Gait disturbance	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		1/10 (10%)
General physical health deterioration	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		0/10 (0%)
Non-cardiac chest pain	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Oedema peripheral	0/11 (0%)		0/9 (0%)		2/22 (9.1%)		0/10 (0%)
Pyrexia	2/11 (18.2%)		1/9 (11.1%)		2/22 (9.1%)		0/10 (0%)
Hepatobiliary disorders
Hyperbilirubinaemia	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		0/10 (0%)
Infections and infestations
Bronchitis	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Device related infection	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Eye infection	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Fungal infection	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		0/10 (0%)
Laryngitis	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		0/10 (0%)
Molluscum contagiosum	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Nasopharyngitis	0/11 (0%)		0/9 (0%)		2/22 (9.1%)		1/10 (10%)
Oral candidiasis	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Otitis externa	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Parotitis	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Pharyngitis	1/11 (9.1%)		1/9 (11.1%)		1/22 (4.5%)		0/10 (0%)
Rhinitis	0/11 (0%)		3/9 (33.3%)		1/22 (4.5%)		0/10 (0%)
Rhinovirus infection	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		0/10 (0%)
Upper respiratory tract infection	1/11 (9.1%)		1/9 (11.1%)		1/22 (4.5%)		2/10 (20%)
Injury, poisoning and procedural complications
Contusion	0/11 (0%)		0/9 (0%)		2/22 (9.1%)		0/10 (0%)
Fall	0/11 (0%)		0/9 (0%)		2/22 (9.1%)		0/10 (0%)
Ligament sprain	0/11 (0%)		0/9 (0%)		2/22 (9.1%)		0/10 (0%)
Upper limb fracture	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		0/10 (0%)
Investigations
Alanine aminotransferase increased	1/11 (9.1%)		1/9 (11.1%)		4/22 (18.2%)		2/10 (20%)
Aspartate aminotransferase increased	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Blood alkaline phosphatase increased	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		0/10 (0%)
Gamma-glutamyltransferase increased	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Urine output decreased	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Weight decreased	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Weight increased	0/11 (0%)		0/9 (0%)		2/22 (9.1%)		0/10 (0%)
Metabolism and nutrition disorders
Decreased appetite	2/11 (18.2%)		0/9 (0%)		3/22 (13.6%)		2/10 (20%)
Hypercalcaemia	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Hyperglycaemia	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		0/10 (0%)
Hypernatraemia	0/11 (0%)		1/9 (11.1%)		1/22 (4.5%)		0/10 (0%)
Hypoalbuminaemia	0/11 (0%)		0/9 (0%)		1/22 (4.5%)		1/10 (10%)
Hypocalcaemia	0/11 (0%)		1/9 (11.1%)		2/22 (9.1%)		1/10 (10%)
Hypokalaemia	2/11 (18.2%)		1/9 (11.1%)		2/22 (9.1%)		2/10 (20%)
Hypomagnesaemia	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Hyponatraemia	0/11 (0%)		0/9 (0%)		2/22 (9.1%)		1/10 (10%)
Hypophosphataemia	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Musculoskeletal and connective tissue disorders
Back pain	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Muscle spasms	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		1/10 (10%)
Muscular weakness	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Pain in extremity	1/11 (9.1%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
Temporomandibular joint syndrome	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haemangioma	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		0/10 (0%)
Nervous system disorders
Aphasia	0/11 (0%)		1/9 (11.1%)		1/22 (4.5%)		0/10 (0%)
Ataxia	2/11 (18.2%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
Depressed level of consciousness	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Dizziness	0/11 (0%)		0/9 (0%)		3/22 (13.6%)		0/10 (0%)
Headache	3/11 (27.3%)		4/9 (44.4%)		5/22 (22.7%)		3/10 (30%)
Hemiparesis	0/11 (0%)		0/9 (0%)		2/22 (9.1%)		0/10 (0%)
Hydrocephalus	0/11 (0%)		1/9 (11.1%)		1/22 (4.5%)		0/10 (0%)
Muscle spasticity	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Paraesthesia	1/11 (9.1%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
Peripheral sensory neuropathy	0/11 (0%)		0/9 (0%)		1/22 (4.5%)		1/10 (10%)
Pyramidal tract syndrome	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Seizure	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Somnolence	0/11 (0%)		0/9 (0%)		1/22 (4.5%)		1/10 (10%)
Tremor	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
VIth nerve disorder	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Psychiatric disorders
Anxiety	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		1/10 (10%)
Confusional state	0/11 (0%)		0/9 (0%)		0/22 (0%)		2/10 (20%)
Insomnia	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		0/10 (0%)
Personality change	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Renal and urinary disorders
Pollakiuria	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Urinary hesitation	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Urinary incontinence	0/11 (0%)		1/9 (11.1%)		1/22 (4.5%)		0/10 (0%)
Urinary retention	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Respiratory, thoracic and mediastinal disorders
Bronchostenosis	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		0/10 (0%)
Cough	1/11 (9.1%)		0/9 (0%)		3/22 (13.6%)		0/10 (0%)
Dyspnoea	1/11 (9.1%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
Hiccups	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		0/10 (0%)
Hypoxia	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Pharyngeal erythema	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Respiratory failure	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		0/10 (0%)
Rhinorrhoea	1/11 (9.1%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
Sleep apnoea syndrome	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Tonsillar inflammation	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		0/10 (0%)
Skin and subcutaneous tissue disorders
Decubitus ulcer	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		0/10 (0%)
Dermatitis acneiform	1/11 (9.1%)		0/9 (0%)		2/22 (9.1%)		1/10 (10%)
Dry skin	1/11 (9.1%)		2/9 (22.2%)		0/22 (0%)		0/10 (0%)
Eczema	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Palmar-plantar erythrodysaesthesia syndrome	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)
Pruritus	2/11 (18.2%)		3/9 (33.3%)		1/22 (4.5%)		1/10 (10%)
Pruritus generalised	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		0/10 (0%)
Rash	2/11 (18.2%)		0/9 (0%)		1/22 (4.5%)		0/10 (0%)
Rash maculo-papular	0/11 (0%)		3/9 (33.3%)		2/22 (9.1%)		2/10 (20%)
Rash pruritic	0/11 (0%)		1/9 (11.1%)		0/22 (0%)		0/10 (0%)
Urticaria	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Vascular disorders
Flushing	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Hypertension	0/11 (0%)		0/9 (0%)		0/22 (0%)		1/10 (10%)
Pallor	1/11 (9.1%)		0/9 (0%)		0/22 (0%)		0/10 (0%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

Results from a center cannot be submitted for publication before results of multicenter study are published unless it is > 1 year since study completion. Then, Investigator can publish if manuscript is submitted to Celgene 60 days prior to submission. If Celgene decides publication would hinder drug development, Investigator must delay submission for up to 90 additional days. Investigator must delete confidential information before submission and defer publication to permit patent applications.